Apparent diffusion coefficient measurements as very early predictive markers of response to chemotherapy in hepatic metastasis: A preliminary investigation of reproducibility and diagnostic value

2013 ◽  
Vol 40 (2) ◽  
pp. 448-456 ◽  
Author(s):  
Filip Deckers ◽  
Bert De Foer ◽  
François Van Mieghem ◽  
Thomas Botelberge ◽  
Reinhilde Weytjens ◽  
...  
Author(s):  
Nada Gamal El-Husseiny ◽  
Sayed Mohamed Mehana ◽  
Sherif Farouk El Zawawy

Abstract Background Colorectal cancer is considered one of the most common causes of cancer-related deaths worldwide. We aim to evaluate the efficacy of DWI-MRI in predicting response to chemotherapy in this cohort. The study included 30 lesions in 20 biopsy proven-colorectal cancer patients with hepatic metastasis larger than 1 cm. All patients underwent both triphasic CT with intravenous contrast, pre-chemotherapy MRI (axial T2 and DW sequences) which was repeated 21 days following chemotherapy. A follow-up CT was done 2 months later. The response of the lesions was evaluated using the RESCIST criteria. On MRI, the lesions corresponding to the ones chosen on CT were identified and the apparent diffusion coefficient (ADC) values of pre- and post-chemotherapy images were recorded and correlated with the CT results. Results In the study, 17 (56.7%) of the lesions showed response to chemotherapy while 13 (43.3%) were non-responding. There was no significant difference in pretreatment ADC values between responding and non-responding lesions (p = 0.14). The mean percentage increase in ADC values in responding lesions was 42% compared to 18% in non-responding lesions (p < 0.001). Lesions that showed less than 18% increase were all found to be non-responsive Conclusion DWI-MRI has an emerging role in early assessment of early treatment response that can be detected before morphological response for patients with hepatic metastasis from colorectal cancer. Based on our study, the use of 25 % as the cutoff point of percent difference in ADC for detection of non-responding lesions proved to be successful only 21 days after the 1st chemotherapy cycle.


Radiology ◽  
2016 ◽  
Vol 281 (1) ◽  
pp. 168-174 ◽  
Author(s):  
Eyal Lotan ◽  
Chen Hoffmann ◽  
Alexander Fardman ◽  
Tomer Ziv-Baran ◽  
Orna Komisar ◽  
...  

2013 ◽  
Vol 2 (7) ◽  
pp. 204798161351248 ◽  
Author(s):  
Shazia Bano ◽  
Mustansar Mahmood Waraich ◽  
Muhammad Afzal Khan ◽  
Saeed Ahmad Buzdar ◽  
Shahid Manzur

Author(s):  
Risa Marissa ◽  
Rachmi Fauziah Rahayu ◽  
Hari Wujoso ◽  
Subandi Subandi ◽  
Prasetyo Sarwono Putro ◽  
...  

BACKGROUNDMeningiomas are the most common primary extra-axial non-glial intracranial tumors. The severe grade of meningioma, according to WHO, has the highest recurrence rate accompanied by high morbidity and mortality rates. Therefore, it is imperative to perform pre-operative assessments so the clinician can give prompt treatment to gain a better prognosis. It is a novel alternative way of predicting meningioma’s malignancy by calculating the tumor’s apparent diffusion coefficient (ADC) value. The objective of the study was to determine the value of ADC for differentiating benign and malignant meningiomas. METHODSThis cross-sectional study involved 32 subjects with clinically diagnosed or histologically verified meningioma (21 benign and 11 malignant). They underwent a head-magnetic resonance imaging (MRI) examination and biopsy. We calculated the ADC value by creating regions of interest (ROIs) on the solid part of the tumor, guided by contrast and fluid-attenuated inversion recovery (FLAIR) sequence. We analyzed the ADC value with independent t-test and Bland-Altman graphs, calculated the average difference, CI 95%, limit of agreement between observers, and ROC. RESULTSMean ADC of malignant meningiomas (0.877 ± 0.167 x 10-3 mm2/s) was significantly lower than that of benign meningiomas (0.990 ± 0.105 x 10-3 mm2/s) (p<0.05). The ADC threshold is 0.886 x 10-3 mm2/s with sensitivity 63.6%, specificity 85.7%, positive predictive value 70% and negative predictive value 81.8%. CONCLUSIONThe ADC value measurement provides a discriminative feature to differentiate between benign and malignant meningiomas. However, the clinical applicability still needs to be elucidated, as histopathological confirmation remains the mainstay of definitive diagnosis.


Sign in / Sign up

Export Citation Format

Share Document